Nanostics, OncoHelix to bring diagnostic tool ClarityDX Prostate to the Middle East

Nanostics and OncoHelix have partnered to bring a groundbreaking diagnostic tool, ClarityDX Prostate, to the Middle East. The collaboration aims to provide men at risk of having aggressive prostate cancer with a more accurate risk assessment, empowering both patients and healthcare providers to make better-informed decisions.

By leveraging cutting-edge AI technology, ClarityDX Prostate represents a major leap forward in prostate cancer diagnostics and early detection.

How does it work?

ClarityDX Prostate is a non-invasive, blood-based diagnostic tool that uses artificial intelligence to analyze biological data and clinical information. By combining these elements with AI-powered learning models, it generates a risk score that indicates the likelihood of a patient having aggressive prostate cancer. This innovative approach helps healthcare providers decide whether a biopsy is necessary following high prostate-specific antigen (PSA) levels or abnormal digital rectal examination (DRE) results.

As Dr. John Lewis, CEO of Nanostics, puts it, "ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early."

This early detection is crucial for improving patient outcomes, especially when determining the best course of treatment.

Why does it matter?

Prostate cancer is one of the most common cancers among men, and early detection can significantly impact survival rates. Traditional diagnostic methods, like PSA testing, often lead to unnecessary biopsies or delayed detection of aggressive forms of cancer. ClarityDX Prostate addresses this gap by offering a more precise risk assessment, reducing the chances of unnecessary procedures while ensuring that high-risk patients receive timely and targeted treatment.

"Partnering with OncoHelix... shows how relevant Alberta-developed technology has become to the world," Dr. Lewis highlights, underscoring the global impact of this diagnostic tool.

By providing more accurate insights, ClarityDX Prostate improves both diagnostic accuracy and the overall quality of care for men at risk.

The context

The introduction of ClarityDX Prostate in the Middle East is facilitated by OncoHelix, which has a strong presence in the region through its OncoHelix-coLAB facility — a collaboration with Burjeel Medical City in Abu Dhabi. This partnership is part of a broader initiative to bring advanced molecular diagnostics and immune profiling to the Middle East and North Africa (MENA) region.

According to Faisal Khan, CEO of OncoHelix, "This advanced diagnostic tool will empower healthcare providers with better, data-driven insights, enabling earlier detection and more targeted treatment."

The availability of ClarityDX Prostate at the OncoHelix-coLAB facility marks an important step in enhancing patient diagnostics and treatment outcomes in the region. The tool is already available in the USA under the name CDX Prostate, distributed by Protean BioDiagnostics, and its expansion into the Middle East showcases its growing global significance.